lancet-header

Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.

Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic

22 Pages Posted: 14 Apr 2020

See all articles by Somayeh Vafaei

Somayeh Vafaei

Iran University of Medical Sciences - Oncopathology Research Center

Mahdieh Razmi

Iran University of Medical Sciences - Oncopathology Research Center

Maryam Mansoori

Iran University of Medical Sciences - Oncopathology Research Center

Mohsen Asadi-Lari

Iran University of Medical Sciences - Oncopathology Research Center

Zahra Madjd

Iran University of Medical Sciences - Cellular and Molecular Research Center

More...

Abstract

2019-nCoV pandemic has influenced on millions of people’s life across the world, which is caused severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or coronavirus disease 2019 (COVID-19). Today, no effective treatment exists; however, scientists are endeavoring to find specific antivirals. The efficacy of several drugs such as remdesivir, ribavirin, favipiravir, oseltamivir and umifenovir are currently undergoing clinical studies in order to discover proper treatment of COVID-19. This article tends to summarize these promising antivirals with potential efficacy against this global challenge. A systematic literature review was performed to screen all of the related papers on COVID-19, using the PubMed, Scopus and Web of Science databases published during five years up to March 22, 2020. We tend to determine the safety and efficacy of remdesivir, ribavirin, favipiravir, oseltamivir and umifenovir. Additionally, we searched Clinicatrial.gov to find ongoing trials. Our search identified seven relevant papers and sixteen ongoing clinical trials. It was clear that there are a few promising therapeutic agents on this horizon. Based on limited evidence in the literature, we suggest that remdesivir treatment, among all of our selected antivirals, accompanied by oxygen inhalations, maintaining fluids, electrolyte and intestinal microbiological modulator balances and nutritional support may be helpful in fighting COVID-19. Based on our systematic results, the use of these antiviral drugs need to be confirmed by ongoing and future clinical trials. The prescription of them in COVID-19 patients should adhere to guidelines to reach better outcome.

Funding Statement: None.

Declaration of Interests: All of authors declare that they have no conflicts of interest to this work.

Keywords: Coronavirus; 2019-nCoV; SARS-CoV-2; COVID-19; Pneumonia; Antiviral Therapy; Systematic Review

Suggested Citation

Vafaei, Somayeh and Razmi, Mahdieh and Mansoori, Maryam and Asadi-Lari, Mohsen and Madjd, Zahra, Spotlight of Remdesivir in Comparison with Ribavirin, Favipiravir, Oseltamivir and Umifenovir in Coronavirus Disease 2019 (COVID-19) Pandemic (4/1/2020). Available at SSRN: https://ssrn.com/abstract=3569866 or http://dx.doi.org/10.2139/ssrn.3569866

Somayeh Vafaei

Iran University of Medical Sciences - Oncopathology Research Center

Tehran
Iran

Mahdieh Razmi

Iran University of Medical Sciences - Oncopathology Research Center ( email )

Tehran
Iran

Maryam Mansoori

Iran University of Medical Sciences - Oncopathology Research Center

Tehran
Iran

Mohsen Asadi-Lari

Iran University of Medical Sciences - Oncopathology Research Center

Tehran
Iran

Zahra Madjd (Contact Author)

Iran University of Medical Sciences - Cellular and Molecular Research Center ( email )

Tehran
Iran